• Corporate
• Markets
• Info-Tech
• Marketing
• Money & Banking
• Agri-Biz & Commodities
• Industry & Economy
• Logistics
• Government
• Opinion
• Variety
• Corporate Results
• Columns
• States
• Web Extras
• Index

• Investment World
• eWorld
• Brand Line
• Mentor
• Life
• Brand Quest
• The New Manager
• BL Club
• Smartbuy
• Books
• Gallery

• Quotes
• SE Diary
• Scoreboard
• Open-End Mutual Fund

• Rates

• Ports

• Yesterday
• Datewise
• Resources
• In Focus
• In Depth
• Events 2007

Subscription

• Business Line

Group Sites

• The Hindu
• Business Line
• Sportstar
• Frontline
• The Hindu eBooks
• The Hindu Images

MUMBAI: Venus Remedies Ltd has informed BSE that the company has bagged its third product patent in South Africa from CIPRO (Companies and Intellectual Property Registration Office) for Potentox after Sulbactomax and Tobracef.

Potentox is a unique super speciality product with a combination of a Cephalosporin with Aminoglycoside recommended for the treatment of hospital acquired pneumonia and community acquired pneumonia and Febrile Neutropenia.

According to the company, this is the fifth product patent achieved by Venus Remedies in the current year.

The company had won its first product patent in South Africa five months ago. — Our Bureau

Prev: Rupee down 11 paise at 46.41/dollar
Next: Opto Circuits in Forbes Asia’s Best Under a Billion list

Copyright copy; 2009, The Hindu Business Line. Republication or redissemination of the contents of this screen are expressly prohibited without the written consent of The Hindu Business Line